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Association between actigraphy-derived physical activity and cognitive 
performance in patients with schizophrenia 
Abstract 
Objective: An association between low levels of physical activity and impaired 
cognitive performance in schizophrenia has been proposed, but most studies have relied 
on self-report measures of activity. This study examined the association between 
actigraphy-derived physical activity and cognitive performance adjusting for multiple 
covariates in patients with schizophrenia. 
Methods: Patients with schizophrenia (n=199) were recruited from chronic psychiatric 
wards, and 60 age-, gender- and BMI-matched comparison participants were recruited 
from the staff of two hospitals and universities. Physical activity was assessed 
objectively for 7 days using an Actigraph. Cognitive performance was assessed with 
the Cognitrone test from the Vienna Test System and the Grooved Pegboard Test. 
Demographic variables, metabolic parameters, positive and negative symptoms, 
duration of illness and hospitalization, and medication use were included as covariates. 
Pearson correlations and multivariable linear regressions were conducted to examine 
the associations between physical activity levels and cognitive performance. 
Results: Patients with schizophrenia were less physically active and had poorer 
performance on attention/concentration and speed of processing than the comparison 
group. Patients with schizophrenia who spent more time in light physical activity 
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showed better performance on attention/concentration (Beta=.198, p=.020) and speed 
of processing (Beta=-.169, p=.048) tasks than those who were less active. Cognitive 
performance was also associated with moderate-vigorous physical activity, but the 
effect was no longer significant once light physical activity had been taken into account. 
Conclusion: This study provides evidence for a positive association between 
objectively measured light physical activity and cognitive performance in people with 
schizophrenia, after adjustment for multiple confounders. 
Keywords: Inactivity; actigraph; accelerometer; psychiatric disorder; cognition 
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Association between actigraphy-derived physical activity and cognitive 
performance in patients with schizophrenia 
Introduction 
Schizophrenia is a chronic and severe mental illness (McGrath et al., 2008, 
National Institute of Mental Health, 2009), resulting in high economic costs (Wu et al., 
2005). People with schizophrenia tend to have a high rate of unemployment (Ramsay 
et al., 2012), an unhealthy lifestyle (e.g. smoking and physical inactivity) (de Leon and 
Diaz, 2005, Wichniak et al., 2011, Yamamoto et al., 2011), and poor physical health 
status (Hausswolff‐Juhlin et al., 2009). Side effects of antipsychotic drugs may 
contribute to an elevated risk of weight gain and the development of metabolic 
disturbances in schizophrenia (Marder et al., 2014, Malchow et al., 2013, Hägg et al., 
2006, Rege, 2008). Moreover, the presence of the metabolic syndrome (MetS) limits 
physical activity in schizophrenia (Vancampfort et al., 2011), leading to a vicious self-
perpetuating cycle of increasing metabolic syndrome and decreasing physical activity 
among patients with schizophrenia. 
The physical health problems and physical activity levels of people with 
schizophrenia have been widely studied (Vancampfort et al., 2011, Ratliff et al., 2012, 
Vancampfort et al., 2013). Another critical issue in schizophrenia is cognitive 
impairment. Cognitive capacity is crucial for functioning in everyday life, since ability 
5 
 
to attend to stimuli selectively, maintain concentration on tasks over prolonged periods, 
use language for communication and self-expression, learn new skills, make decisions, 
and execute actions are all important (Sharma and Antonova, 2003, Glisky, 2007). 
These abilities are impaired to some extent in patients with schizophrenia, with deficits 
in attention, executive function, verbal and visuospatial working memory, and learning 
and memory having been reported (Sharma and Antonova, 2003). Cognitive deficits 
are also associated with impaired functional status, work capacity, social behavior, and 
activities of daily living (Matza et al., 2006, Green, 1996).  
The benefits of physical activity for cognitive performance are well documented 
in healthy populations (Angevaren et al., 2008, McMorris and Hale, 2012, Guiney and 
Machado, 2013, Verburgh et al., 2014). However, the impact of physical activity on 
individuals with mental illness has only recently been examined (Richardson et al., 
2005, Holley et al., 2011, Zschucke et al., 2013). The available evidence suggests that 
high physical fitness or more physical activity are associated with better cognitive 
performance, including executive functioning, verbal working memory, and speed of 
processing among patients with schizophrenia (Kimhy et al., 2014, Leutwyler et al., 
2014). These findings indicate that physical activity might have potential benefits for 
some domains of cognition in people with schizophrenia. 
However, most studies have used self-report measures of physical activity, and 
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these are subject to recall bias (Lindamer et al., 2008). The few studies examining 
associations between objectively-measured physical activity and cognition in people 
with schizophrenia have been small scale (Leutwyler et al., 2014, Lindamer et al., 2008). 
Moreover, potentially confounding factors, such as education levels, body mass index 
(BMI), MetS parameters, antipsychotic medication, smoking and drinking status have 
not been controlled (Leutwyler et al., 2014). This study was therefore designed to 
examine the association between actigraphy-derived physical activity and cognitive 
performance while adjusting for multiple confounders in people with schizophrenia. 
Methods 
Participants 
Participants were recruited from the chronic psychiatric wards at Jianan Mental 
Hospital, Taiwan. The diagnosis of schizophrenia was verified by psychiatrists based 
on the Diagnostic and Statistical Manual Disorders, Fourth Edition. Patients were 
included if they were stable on antipsychotic medicine and had used the same dosage 
for at least three months prior to inclusion. Those who were unable to communicate, 
unable to walk independently, and had neurological disorders were excluded. A total of 
200 potential inpatients were suitable for the study. Among them, 199 inpatients 
provided their written informed consent. 
Age-, gender- and BMI-matched comparison participants were recruited from 
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the staffs of two hospitals and universities. Individuals who had no present or past 
history of psychiatric disorder and were not taking any psychoactive medicines were 
invited. A total of 60 participants were selected to ensure comparable gender balance, 
age and BMI ranges to the schizophrenia group. The study was approved by the 
Institutional Review Board of Jianan Mental Hospital. 
Measures 
Physical activity 
The wActiSleep-BT ActiGraph (Pensacola, FL, USA), was used to assess 
physical activity levels objectively. This is a tri-axial accelerometer that has been 
validated and used in previous studies (García-Ortiz et al., 2010, Hansen et al., 2012, 
Cain et al., 2013, de Moura et al., 2015). Standardized instructions of wearing an 
accelerometer were provided by research assistants. Participants were asked to wear the 
accelerometer all day on the wrist of the non-dominant hand for one week and to 
remove it during bathing or water activities. The accelerometers were initialized, 
downloaded and analyzed using ActiLife software version 6 (ActiGraph LLC). The 
sleep period was excluded and the levels of physical activity were defined according to 
the cut-off points outlined by Freedson (Freedson et al., 1998). Light physical activity 
was defined as counts between 101 and 1951, and time in moderate-vigorous physical 
activity (MVPA) was defined as activities≧1952 cpm (Cain et al., 2013, Lindamer et 
8 
 
al., 2008). Participants were excluded if the accelerometers were not worn for at least 
10 hours per day (excluding sleep period) for at least 5 days (n=38). The average wear 
time was 13.9±2.1 hours per day for the schizophrenia group and 16.3±1.4 hours per 
day for the healthy controls. 
Cognitive function 
Vienna Test System (VTS). The VTS is a computerized neurocognitive function 
assessment battery consisting of various tests of personality, intelligence, and cognitive 
function (Schuhfried, 2013). It has been used in previous studies of healthy individuals, 
people with depression (Deijen et al., 1993, Lee et al., 2003), and people with 
schizophrenia (Klasik et al., 2011). The Cognitrone test (COG) used in this study is a 
general ability test assessing attention and concentration. Participants are presented 
with a series of abstract figures on the computer screen, and make judgments 
concerning their congruence (Schuhfried, 2013). The number of responses made within 
the total working time of 7 minutes was recorded. 
Grooved Pegboard Test (GPT). The GPT is regarded as a test of manual 
dexterity, upper-limb motor speed, hand-eye coordination, and speed of processing and 
has been widely used in previous research (Bezdicek et al., 2014, Belsky et al., 2015, 
Wang et al., 2011, Nuechterlein et al., 2004). It consists of 25 holes with randomly 
positioned slots. The task involves inserting pegs into the board in a fixed order and in 
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the correct direction using only one hand. Participants are encouraged to perform the 
task as quickly as possible, and the total time needed for the test is recorded. In this 
study, participants were tested twice, once with the dominant hand and once with the 
non-dominant hand, and the average time taken for the two tests was calculated. 
Covariates 
Positive and negative syndrome scale (PANSS). The PANSS was developed to 
assess the severity of positive and negative symptoms and to measure general 
psychopathology in schizophrenia (Kay et al., 1987). It was completed by the registered 
nurses looking after each patient with schizophrenia. The 30-item rating scale consists 
of three subscales: 7-item Positive Symptoms, 7-item Negative Symptoms, and 16-item 
General Psychopathology. Each item is assessed on a 7-point rating scale ranging from 
1 (asymptomatic) to 7 (extremely symptomatic). The PANSS was summed across items, 
so could range from 7 to 49 for the Positive and Negative Scales and 16 to 112 for the 
General Psychopathology Scale. Higher scores indicate more severe symptoms.  
Medication use. Information about years since illness onset, duration of 
hospitalization, the use of antipsychotics medication and sleeping pills was collected 
from hospital records. Antipsychotic medication use was converted into a daily 
equivalent dosage of chlorpromazine (Gardner et al., 2010), while sedatives were 
converted to the daily equipotent dosage of Lorazepam, according to the defined daily 
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dose (DDD) of WHO Collaborating Centre for Drug Statistics Methodology 
(http://www.whocc.no/ddd/definition_and_general_considera/). 
Metabolic parameters. Waist circumference, systolic/diastolic blood pressure 
(SBP/DBP), serum triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), 
and fasting glucose (FG) were obtained through regular health checks in the hospital. 
Demographic variables. Data on age, sex, smoking habits, alcohol consumption, 
and years of schooling were collected. Participants were categorized into two groups: 
‘Yes (current/former smoker or drinker)’ and ‘No’ (never). Groups of current and 
former smoker or alcohol consumer were combined, due to there being few current 
smokers (n=18) or current alcohol consumers (n=2). Body weight and height were 
measured in light clothes and body mass index (BMI) was calculated.  
Psychiatric nurse practitioners who had completed psychiatric professional 
training and research ethics training to degree level or higher administered the tests. 
Statistical analyses 
Descriptive statistics were calculated and Chi-square tests and t-tests were 
performed to compare schizophrenia and comparison groups. Pearson correlations were 
used to test the univariate associations between physical activity levels and cognitive 
performance in each group. To examine the independent association between physical 
activity levels and cognition, multivariable linear regression analyses were conducted. 
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Separate regressions were conducted for each of the cognitive measures and groups. 
Results are presented in terms of standardized (beta) regression coeffients and 
associated p values. All models were adjusted with demographic variables (age, sex, 
education), behavioral variables (smoking and alcohol consumption), metabolic 
parameters, and accelerometer wear time in the comparison group. Clinical factors 
(years since illness onset, duration of hospitalization, medication use, and PANSS) were 
additional covariates in patients with schizophrenia. All analyses were performed with 
IBM SPSS statistics 20 and a p-value less than 0.05 was considered as statistically 
significant in this study. 
Results 
Table 1 shows the descriptive statistics for participants with and without 
schizophrenia. It can be seen that patients with schizophrenia were aged 44 on average, 
with a slight majority of men. They were long-term patients averaging 23.8 years since 
diagnosis, and had been hospitalized for an average of 14.2 months. There was no 
significant difference between the patients with schizophrenia and the non-psychiatric 
comparison group in respect to age, sex, and BMI. However, patients with 
schizophrenia had poorer performance on the GPT and the COG test than the 
comparison group (all p<.001). 
 Participants with schizophrenia spent 158.6 mins/day in light physical activity, 
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which was significantly fewer than the comparison group (496.0 mins/day). The time 
spent in MVPA was also less in the schizophrenia group (95.0 mins/day) than the 
comparison group (154.5 mins/day). The remaining time was spent in sedentary 
activities. These findings indicate that patients with schizophrenia were less active than 
the comparison group. Additionally, the schizophrenia group had greater waist 
circumference, higher TG and FG, and lower HDL-C than the non-psychiatric 
comparison group (Table 1). 
Table 1 
The univariate associations between physical activity levels and cognitive 
performance among patients with schizophrenia and the comparison group are shown 
in table 2. Significant associations were found between each level of physical activity 
and all cognitive measures among people with the schizophrenia, so spending more 
time in any intensity of physical activity was related to better performance on the GPT 
and COG test. However, no significant association was found between any level of 
physical activity and the cognitive measures in the comparison group. 
Table 2 
The fully adjusted linear regressions relating physical activity with cognitive 
performance in patients with schizophrenia are presented in Table 3. Light physical 
activity and MVPA were entered separately into regression models. Significant 
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associations were found between the amount of activity at each level of physical activity 
and the two cognitive measures even after multivariable adjustments (Light: Beta=.224, 
p=.002 in COG, Beta=-.245, p=.001 in GPT; MVPA: Beta=.167, p=.036 in COG, 
Beta=-.254, p=.001 in GPT, respectively). The results suggest that participating in more 
light physical activity or MVPA was associated with better cognitive performance 
among patients with schizophrenia. 
Table 3 
In order to determine the relative contributions of physical activity levels to 
cognitive performance, light physical activity and MVPA were simultaneously entered 
as independent variables into regression models with multivariable adjustments (Table 
4). Interestingly, the relationship was stronger for light activity than for MVPA in the 
schizophrenia group. Patients with schizophrenia who spent more time doing light 
activity had better performance on COG (Beta=.198, p=.020) and GPT (Beta=-.169, 
p=.048) tasks. However, MVPA was not associated with any cognitive measures in the 
presence of light physical activity and other covariates. 
No significant association was found in multivariable regression models 
between levels of physical activity and cognitive performance in the comparison group. 
The fully adjusted models are shown in Table 4. 
Table 4 
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Discussion 
This study showed lower physical activity levels in patients with schizophrenia 
compared with a non-psychiatric comparison group. Within the schizophrenia group, 
higher levels of objectively measured light physical activity were associated with better 
performance on both cognitive tests independently of demographic factors such as age, 
sex and schooling, physiological risk factors, schizophrenia symptoms, duration of 
illness and hospitalization, or medication. The amount of MVPA was also associated 
with cognitive performance, but not after light activity and other covariates were 
included in the models. 
The difference in physical activity between patients with schizophrenia and 
healthy controls is consistent with the findings from previous research (Yamamoto et 
al., 2011, Wichniak et al., 2011). However, Lindamer, et al. found no significant 
difference in physical activity measured with accelerometry between the two groups 
(Lindamer et al., 2008). One of the reasons might be the age difference of the sample 
between studies. Lindaner et al. (2008) included older adults (mean age 50.7±6.4), 
while the mean age of the participants in our study was younger. Moreover, participants 
in the earlier study were outpatients, whereas our study only included inpatients. The 
small sample size with valid accelerometry data in the earlier study (16 from people 
with schizophrenia and 6 from the comparison group) may have resulted in lack of 
15 
 
statistical power to make the comparison. Hospitalisation and duration of illness might 
also contribute to the different findings of other studies (Wichniak et al., 2011). 
It should be noted that the people with schizophrenia in this study were all 
inpatients, while the comparison group was free living. This makes it difficult to 
conclude whether differences are the result of the mental illness of the patient group, or 
whether differences are due to restrictions in activity in the hospital environment. The 
hospital which housed the patients has an indoor gym where patients can play table 
tennis, basketball, and snooker, and stationary bikes and treadmills are also available. 
Patients were also encouraged to attend 20-minute stretching and walking sessions in 
the morning and afternoon. However, with hundreds patients and limited facilities, 
patients may be restricted in the space and time available to engage in physical activity. 
The current study also indicated that spending more time on light activity was 
associated with better cognitive performance on attention/concentration and processing 
speed in patients with schizophrenia. The relationship was stronger for light activity 
than for MVPA. A similar study using objective physical activity measures found 
significant associations of moderate physical activity with speed of processing and 
verbal working memory among 30 older schizophrenia participants; however, no 
significant association between other cognitive measures and physical activity was 
found (Leutwyler et al., 2014). The inconsistent findings may be due to difference in 
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physical activity categorisation. Sedentary and light activities were combined into one 
level by Leutwyler et al. (2014). It is more appropriate to separate sedentary from light 
physical activity, since low activity is commonly found in patients with schizophrenia 
(Yamamoto et al., 2011), and the association of sedentary and light activities with 
cognitive performance might differ (Steinberg et al., 2015). We further tested the 
associations of sedentary and light activity with cognitive performance in the present 
study (results not shown). The findings confirm that light activity but not sedentary 
activity was associated with better cognitive performance. 
Additionally, no significant association was found between any level of physical 
activity and either cognitive test in the non-psychiatric comparison group. This 
contrasts with substantial literature showing positive relationships (Angevaren et al., 
2008, McMorris and Hale, 2012, Guiney and Machado, 2013, Verburgh et al., 2014). 
One of the reasons might be the small size of the comparison group. Moreover, 
individuals in the comparison group generally had good cognitive performance, leaving 
little scope for observing any effects of physical activity. 
Physical activity interventions may be particularly appealing for individuals 
with mental illness, in hospital settings, since they are relatively safe, low cost, and 
easily integrated into daily schedules (Richardson et al., 2005). Studies have shown 
enhancement in composite cognitive test scores (Kimhy et al., 2015), hippocampal 
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volume, short-term memory (Pajonk et al., 2010), working memory, and speed of 
processing (Oertel-Knöchel et al., 2014) in patients with schizophrenia after aerobic 
exercise training, although not all results have been positive (Scheewe et al., 2013, 
Falkai et al., 2013). However, previous research has mainly focused on the effects of 
MVPA. Promoting light physical activity might be more feasible than MVPA among 
patients with schizophrenia, since they spend much of the time in sedentary activities. 
This study has demonstrated that even light physical activity is associated with better 
cognitive performance in people with schizophrenia. 
The current study provides evidence of positive associations between light 
physical activity and cognitive performance in patients with schizophrenia after taking 
multiple potential confounders into account. However, interpretation of the results is 
limited by the cross-sectional design, which is not able to determine causal relations. 
All the participants with schizophrenia were long-term psychiatric in-patients, and 
findings might not generalize to less severe out-patients. Moreover, this study only 
included two cognitive tests and did not collect information about menstrual status, 
which may impact cognitive performance and physical activity in female patients. 
Well-designed prospective cohort studies or randomized controlled trials are needed to 
establish whether light and moderate physical activity can improve cognitive function 
among patients with schizophrenia. 
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Table 1: Characteristics of individuals with and without schizophrenia 
 Percentages (%) or Means (sd) 
 
 Schizophrenia Comparison group P 
Demographic variables N=199 N=60  
Age 44.0(9.9) 41.1(9.6) .052 
BMI 24.3(4.3) 23.9(3.7) .520 
Sex (Male) (%) 61.3 56.7 .520 
Smoke (Never) (%) 57.3 81.7 .001 
Alcohol (Never) (%) 83.4 85.0 .771 
Schooling (years) 
 
11.4(2.2) 14.9(3.5) <.001 
MetS a parameters    
Waist circumference 86.8(11.1) 81.0(10.5) <.001 
SBP b 112.6(13.2) 114.5(11.9) .303 
DBP c 71.2(8.8) 73.4(7.0) .053 
TG d 133.6(71.7) 106.8(64.3) .010 
HDL-C e 47.0(13.3) 54.5(16.1) .001 
FG f 
 
100.2(28.8) 93.9(11.3) .012 
Physical activity level    
Light PA (mins/day) 158.6(71.4) 496.0(90.1) <.001 
MVPA (mins/day) g 
 
95.0(54.2) 154.5(72.1) <.001 
Cognitive Function    
COG h 171.9(100.5) 392.4(134.3) <.001 
GPT (sec) i 137.7(45.6) 72.4(32.1) <.001 
 
PANSS j 
63.0(20.0)   
PANSS_P 15.4(5.7)   
PANSS_N 16.9(6.2)   
PANSS_G 30.7(10.7)   
 
Medications (mg/d) 
   
Chlorpromazine 
equivalent doses  
847.6(783.8) 
  
Lorazepam equivalent 
doses 
1.1(1.3) 
  
 
Years since illness onset 
23.8(6.5) 
  
Duration of 
hospitalization (month) 
 
14.2(17.0) 
  
a: Metabolic syndrome; b: Systolic blood pressure; c: Diastolic blood pressure; d: 
Triglyceride; e: High-density lipoprotein cholesterol; f:: Fasting glucose; g: 
Moderate-vigorous physical activity; h: Cognitrone; i: Grooved Pegboard Test; j: 
Positive and negative syndrome scale.
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Table 2: Correlations of physical activity with cognitive performance in people with and without 
schizophrenia 
 
 Light PA MVPA COG GPT 
Patients with schizophrenia     
Light PA 1       
MVPA .551** 1     
COG .217** .300** 1   
GPT -.287** -.368** -.412* 1 
Comparison group     
Light PA 1       
MVPA .153 1     
COG .172 .125 1   
GPT -.177 -.224 -.466** 1 
 
MVPA: Moderate-vigorous physical activity; RT: Reaction time; 
COG: Cognitrone;  
GPT: Grooved Pegboard Test.  
**
Correlation is significant at the 0.01 level (2-tailed). 
Patients with schizophrenia: n=199; Comparison group: n=60 
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Table 3: Multivariable linear regressions relating cognitive function with physical activity levels in participants with schizophrenia  
 
Variables 
Light physical activity MVPA g 
COG i GPT j COG i GPT j 
R2 Beta p R2 Beta p R2 Beta p R2 Beta p 
 29.4   28.2   27.4   27.8   
Age  -.264 <.001  .262 <.001  -.229 .003  .203 .009 
Sex a  .036 .687  -.030 .745  .029 .756  -.013 .885 
Smoke a  .047 .559  -.060 .457  .047 .569  -.045 .584 
Alcohol a  -.025 .726  .129 .072  -.031 .666  .136 .059 
Schooling  .047 .487  -.092 .184  .072 .295  -.122 .078 
MetS parameters             
Waist  .022 .775  .016 .839  .021 .784  .016 .834 
SBP b  -.227 .014  -.046 .619  -.201 .031  -.070 .446 
DBP c  .223 .014  .074 .417  .224 .015  .065 .480 
TG d  .051 .485  -.058 .433  .045 .551  -.048 .523 
HDL-C e  -.021 .776  .011 .880  .010 .890  -.023 .763 
FG f  .028 .694  .060 .401  -.007 .923  .099 .162 
Physical Activity             
Light  .224 .002  -.245 .001       
MVPA g        .167 .036  -.254 .001 
PANSS h             
PANSS-P  -.151 .068  .249 .003  -.117 .162  .205 .015 
PANSS-N  -.316 .005  .181 .106  -.251 .028  .093 .409 
PANSS-G  .140 .268  -.141 .271  .092 .470  -.085 .505 
Medications             
Chlorpromazine 
equivalent doses 
 .154 .026  .094 .179  .142 .043  .104 .137 
Lorazepam equivalent 
doses 
 -.092 .176  .003 .961  -.101 .144  .021 .766 
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Years since illness onset  .004 .952  -.012 .864  .017 .819  -.042 .565 
Duration of 
hospitalization (month) 
 -.115 .098  .007 .922  -.183 .228  -.022 .750 
a: Dummy variable; b: Systolic blood pressure; c: Diastolic blood pressure; d: Triglyceride; e: High-density lipoprotein cholesterol; f:: Fasting glucose; 
g: Moderate-vigorous physical activity; h: Positive and negative syndrome scale. i: Cognitrone; j: Grooved Pegboard Test. 
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Table 4: Multivariable linear regressions relating cognitive function with physical activity levels in participants with and without schizophrenia 
 
Variables 
Patients with schizophrenia Comparison group 
COG i GPT j COG i GPT j 
R2 Beta p R2 Beta p R2 Beta p R2 Beta p 
 29.6   29.4   55.8   56.3   
Age  -.250 <.001  .222 .004  -.187 .208  .275 .066 
Sex a  .032 .727  .016 .861  .214 .165  .122 .423 
Smoke a  .039 .628  -.039 .635  -.062 .696  -.203 .200 
Alcohol a  -.026 .720  .131 .066  -.039 .755  .121 .330 
Schooling  .052 .451  -.105 .130  .344 .019  -.514 .001 
MetS parameters             
Waist  .022 .775  .016 .839  -.059 .705  .138 .375 
SBP b  -.225 .015  -.050 .591  -.243 .146  -.281 .092 
DBP c  .227 .013  .062 .491  .130 .345  -.079 .560 
TG d  .049 .507  -.051 .487  -.100 .502  -.031 .836 
HDL-C e  -.018 .813  .001 .986  .129 .393  .019 .898 
FG f  .023 .746  .073 .302  -.317 .006  .178 .107 
Physical Activity             
Light  .198 .020  -.169 .048  .034 .791  -.139 .275 
MVPA g  .054 .551  -.158 .085  .124 .325  -.100 .425 
PANSS h             
PANSS-P  -.144 .086  .227 .007       
PANSS-N  -.300 .009  .135 .238       
PANSS-G  .133 .296  -.120 .347       
Medications             
Chlorpromazine 
equivalent doses 
 .154 .027  .094 .178       
Lorazepam equivalent 
doses 
 -.096 .159  .016 .811       
Years since illness onset  .001 .985  -.029 .691       
Duration of  -.114 .101  .005 .947       
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hospitalization (month) 
a: Dummy variable; b: Systolic blood pressure; c: Diastolic blood pressure; d: Triglyceride; e: High-density lipoprotein cholesterol; f:: Fasting glucose; 
g: Moderate-vigorous physical activity; h: Positive and negative syndrome scale. i: Cognitrone; j: Grooved Pegboard Test. 
 
